FDA D.I.S.C.O.: FDA approval of cabozantinib for hepatocellular carcinoma
Release Date:
FDA D.I.S.C.O.: FDA approval of cabozantinib for hepatocellular carcinoma
FDA medical oncologists discuss the January 14, 2019, approval of cabozantinib for patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.
FDA D.I.S.C.O.: FDA approval of cabozantinib for hepatocellular carcinoma